The Europe-wide approval is the first ever insulin treatment licensed through the European Medicines Agency's biosimilar pathway, and the fourth diabetes product approved in the EU from the Lilly ...
Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback